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A B S T R A C T
Purpose
We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of
anticoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs.
Patients and Methods
Patients with active cancer and a first episode of DVT treated with low molecular weight heparin
(LMWH) for 6 months were eligible. Patients were managed according to RVT findings: those with
RVT were randomly assigned to continue LMWH for an additional 6 months (group A1) or to
discontinue it (group A2), and patients without RVT stopped LMWH (group B). The primary end
point was recurrent venous thromboembolism (VTE), and the secondary end point was major
bleeding. Patients were observed for 1 year after LMWH discontinuation.
Results
Between October 2005 and April 2010, 347 patients were enrolled. RVT was detected in 242
patients (69.7%); recurrence occurred in 18 of the 119 patients in group A1compared with 27 of
123 patients in group A2. The adjusted hazard ratio (HR) for group A2 versus A1 was 1.58 (95%
CI, 0.8 to 3.0; P  .175). Three of the 105 patients in group B developed recurrent VTE; adjusted
HR for group A1 versus B was 6.0 (95% CI, 1.7 to 21.2; P  .005). Three major bleeding events
occurred in group A1, and two events each occurred in groups A2 and B (P  .880). Overall, 42
patients (12.1%) died during follow-up as a result of cancer progression.
Conclusion
In patients with cancer with a first DVT, treated for 6 months with LMWH, absence of RVT
identifies a population at low risk for recurrent thrombotic events. Continuation of LMWH in
patients with RVT up to 1 year did not reduce recurrent VTE.
J Clin Oncol 32. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Venous thromboembolism (VTE) is a frequent
complication in patients with cancer.1-3 Manage-
ment of deep vein thrombosis (DVT) and/or pul-
monary embolism (PE) may be difficult in this
populationbecauseof thehighriskofbothrecurrent
events and major hemorrhages, even if adequate
vitamin K antagonist (VKA) therapy is adminis-
tered.4 It has been reported that the use of low mo-
lecular weight heparin (LMWH) is more effective
than VKA,5 and LMWH is now recommended as
the first option for patients with any type of cancer
who have acute VTE.6,7 There is less evidence re-
garding the duration of anticoagulant treatment;
current guidelines suggest that patients with cancer-
relatedDVT should be treated for 6months or even
longer6 if the cancer is still active, but such recom-
mendations are not based on randomized trials, and
thus there is some uncertainty. In noncancer pa-
tients, the risk of recurrence is usually greatest dur-
ing the first year after treatment withdrawal and
graduallydiminishes,8 although the increasedbleed-
ing risk may offset the benefits of prolonged ther-
apy.9 For this reason,new immediately available and
easily determinable markers, such as residual vein
thrombosis (RVT) and the D-dimer test, have been
proposed to individualize treatment for secondary
prevention of VTE.10-13 Results from prospective
studies have shown that the absence of RVT or a
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negativeD-dimer testmay support the safewithdrawal ofVKA from3
to6monthsafterDVT.10Conversely,RVThasbeenassociatedwithan
increased risk for recurrent VTE in both idiopathic and provoked
DVT.11-13 In comparison to the D-dimer, RVT is not influenced by
factors acting on blood coagulation. The use of RVT to optimize the
duration of LMWHtreatment in patients with cancerwith acuteVTE
is still unexplored.
We therefore performed a randomized study in patients with
cancerwith a first episode of symptomatic lower-limbDVT to test the
hypothesis that RVTmay be used to determine the optimal duration
of LMWH treatment.
PATIENTS AND METHODS
Study Population
Inclusion criteria were age  18 years; symptomatic proximal DVT
detected by compression ultrasonography (C-US); and active cancer, defined
as metastatic or locally advanced lung, GI (stomach, colon, or rectum), pan-
creatic, breast, ovarian, or head and neck cancer or blood cancer treated with
LMWH for 6months after the index event.5 Patients with active cancer and a
DVTepisodeoccurring after surgery for cancerwere also eligible for the study.
Exclusion criteria were Eastern Cooperative Oncology Group performance
status more than 2; previous VTE; antiphospholipid antibody syndrome, or
other known thrombophilic states (eg, deficiency in antithrombin, protein C
and S, homozygosity for factor V Leiden or factor II G20210A mutations or
heterozygous combinations thereof); conditions not otherwise specified that
required prolonged anticoagulation as for any previous thrombosis; active
bleeding or bleeding requiring hospitalization, transfusion, or surgery in the
past 4weeks; intracranial bleedingover thepast 6months;high riskofbleeding
(international normalized ratio or activated partial thromboplastin time ra-
tio 1.3 or a platelet count 75 109/L)5; active gastric or duodenal ulcer;
cerebral metastases; severe and uncontrolled hypertension; creatinine clear-
ance less than 30 mL/min; severe liver insufficiency; or unavailability for
follow-up.Patientsdidnotundergo imaging forPE if theywereasymptomatic.
Patients who were symptomatic for PE or who had an imaging result positive
for PE were excluded (Fig 1).
The study was carried out in accordance with the provisions of the
Declaration of Helsinki and local regulations. Eligible patients were enrolled
after written informed consent was provided. The protocol was approved by
the institutional review board at each study center.
Study Design and Procedures
This multicenter prospective study was carried out between October
2005andApril 2010.Atenrollment, 6months fromthe indexDVT,allpatients
underwentC-USof the affected andcontralateral leg. Each enrollingphysician
had to have experience in C-US or received an appropriate training on C-US.
Imageswereobtained fromthe transverse sectiononly.Lumencompressibility
was thenevaluatedbygentlepressureof theprobe;RVTdiameterwas takenby
measuring the distance between the anterior andposteriorwalls of the vein on
freeze-frame B-mode images during compression with the ultrasound
probe.14 The examination was performed with the patient in the supine posi-
tion with the leg externally rotated and slightly flexed at the knee. Measure-
ments were taken at the common femoral vein 1 cm below the inguinal
ligament and at the popliteal vein at the most prominent crease in the midp-
opliteal fossa. RVT was calculated12 according to the following formula:
RVT vein diameter during compression (diameter B) 100/vein diameter
before compression (diameter A). RVT was arbitrarily scored as absent when
the value was less than 40% of vein diameter. The patient was considered to
have RVT when a persisting thrombus was present in at least one of the two
examined segments (Fig 2) in each leg.The choiceof vein segments to examine
was based on the evidence that, from proximal to distal veins, the specificity
and reproducibility of the method declines with a high risk of false results
distally to the popliteal vein.
Patients with RVT were then randomly assigned to either continue
LMWH(nadroparine)or stop it (groupsA1andA2, respectively).Nadroparin
was administered at 75% of full dose (97 IU anti–activated coagulation factor
X per kilogram twice daily) for 6 additional months on the basis of the results
of randomized studies that evaluated LMWH in comparison to VKA,5,15 and
it was administered at this fixed dose for the entire duration of the study. All
patients with no evidence of RVT stopped anticoagulation (groupB; Fig 3).
After the first C-US performed at the time of enrollment, patients under-
went additional testing in addition to scheduled follow-up visits only when
recurrence was clinically suspected. Fatal PE as a cause of death was
excluded on the basis of the absence of clinical symptoms or on normal
imaging results.
Random Assignment
Patients with RVT were allocated to either stop or continue LMWH.
Randomassignmentwasdeterminedby a sealed-envelope techniquebasedon
clinical chart number with a block size of 10. Patients and treating physicians
were not masked to treatment or status of RVT.
Study Outcomes and Follow-Up
All enrolled patients were observed for 1 year after LMWH discontinu-
ation (Fig 3) and were seen at their reference center at intervals of 3 months.
Assessed for eligibility
(N = 409)
Patients with RVT
Randomly allocated (n = 242)
Patients without RVT
Not randomly (n = 105)
  allocated
Allocated to intervention (n = 119)
  Received allocated (n = 119)
    intervention
Allocated to intervention (n = 123)
  Received allocated  (n = 123)
    intervention
Analyzed (n = 119)
)21 = n( deiD
Analyzed (n = 105)
Died (n = 11)
Analyzed (n = 123)
)91 = n( deiD
)26 = n( dedulcxE
  Did not meet inclusion criteria (n = 53)
  Declined to participate (n = 9)
Fig 1. CONSORT diagram. Trial profile.
RVT, residual vein thrombosis.
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Follow-up visits consisted of clinical examination and laboratory and imaging
tests to check for persistent active cancer when needed; C-US was not per-
formedat these contacts. Follow-upvisits lasted18months ingroupA1and12
months in groups A2 and B. Uniformity of follow-up visits wasmonitored by
regular computer checking in each center.
Theprimary endpointwas the time to recurrentVTE, and the secondary
end point was major bleeding. The choice of the primary outcome measure
derives from the interest in evaluating the opportunity of prolonged treat-
ments of DVT in patients with cancer, assuming that all patients undergo
standard 6months of treatment. Patientswere instructed to contact the center
if symptoms suggestive of VTE or bleeding developed. The following symp-
toms were suggestive of RVT: pain, increased volume, or temperature or
redness of the leg. In cases of recurrence, C-USwas performed, and test results
were compared with baseline. Diagnosis of recurrent DVT was made if a
previously fully compressible segmentbecameno longer compressible, or if an
increase of more than 4 mm in the diameter of the residual thrombus during
compressionwasdetected16; inundeterminedcases, repetitionof the test (after
5 to 7 days) or contrast venography was performed. In patients with possible
PE, diagnosis of recurrence was based on objective algorithms with the use of
clinical probability, ventilation-perfusion lung scanning, or helical computed
tomography.17,18 Major bleeding was defined as a decrease in hemoglobin of
more than 2.0 g/dL, intracranial or retroperitoneal bleeding, bleeding requir-
ing surgery or blood transfusion, or any other bleeding necessitating suspen-
sion of anticoagulation and hemostatic approaches.9Minor bleeds comprised
all other events. All outcomes and deaths were evaluated by a central commit-
tee whose members were unaware of the patient’s name, enrolling center,
results of RVT assays, and group assignment. Committee members also re-
viewed all the results of clinical investigations.
Statistical Analysis
The sample size was calculated, taking into account an incidence of 20%
for recurrent thrombotic events for the group with the best prognosis (group
B),4 and postulating an event rate of 20% in group A1 and 30% in group A2.
An overall sample size of 300 patients (100 for each study group) was calcu-
lated (SPSSSamplePower, version3.0.1; IBM,Chicago, IL) to achieve apower
of 80% to document a difference of at least 15% in at least one of the
different head-to-head comparisons on the basis of the Bonferronimethod
for distributing type I error (0.05) amongmultiple comparisons. To mon-
itor the safety of the trial, a safety analysis was planned after enrollment of
two thirds of the total patient population. Before study onset, we set up an
internal quality control system to assess intra- and interexaminer repro-
ducibility for RVT analysis among operators by using Cohen’s unweighted
 test.19
Baseline differences between groups were assessed by the 2 test (Yates’
correction) for categorical variables, and the univariable analysis of variance
for parametric analyses. A Kaplan-Meier curve (log-rank test) was used to
estimate the cumulative probability of symptomatic recurrent vein throm-
bosis events. Hazard ratios (HRs) for the treatment effects and their 95%
CIs were calculated by using the Cox proportional hazards models and
were adjusted for age, sex, previous surgery, and presence of metastasis.
Data were analyzed on an intention-to-treat basis by using Epi Info soft-
ware, version 6.0 (Centers for Disease Control and Prevention, Atlanta,
GA) and SPSS Software, version 14.0 (SPSS, Chicago, IL). All P values were
two-tailed; Bonferroni-adjusted P values less than .05 were considered
statistically significant.
RESULTS
Patients and Treatment Groups
Of the 409 evaluated patients, 62 were excluded: nine did not
provide informed consent, 18 required long-term anticoagulation,
Having received
6 months of LMWH
LMWH
No LMWH
Follow-up
18 months
VTE Bl F
Group Major Minor
A1 4 4 2 108 10 2 4 91 8 1 3 78
A2 18 1 4 94 9 1 4 77
B 2 1 3 97 1 1 2 91
VTE Bl F
Major Minor
12 months6 months
VTE Bl F
Major Minor
RVT R
No RVT
CUS
T12T6T0 T18
A1
A2
B
Fig 3. Study design. A1 indicates pa-
tients with residual vein thrombosis (RVT)
who continued low molecular weight hep-
arin (LMWH) for an additional 6 months;
A2 indicates patients with RVT randomly
assigned to stop LMWH treatment; B
indicates patients without RVT who stopped
LMWH treatment. C-US, compression ultra-
sonography; DVT, deep vein thrombosis; R,
randomization; Time 6, after 6 months; Time
12, after 12 months; Time 18, after 18
months.
RVT positive RVT negative
Clot
Clot
Clot
Clot
Diameter A
Diameter B
Thrombus occupying
≤ 40% of the
vein diameter
Thrombus occupying
> 40% of the
vein diameter
Before
vein compression
During compression
Fig 2. Evaluation of residual vein thrombosis (RVT). RVT was calculated
according to the following formula: RVT  vein diameter during compression
(diameter B)  100/vein diameter before compression (diameter A).
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sevenhad lowplatelet count, 12 had recent surgery, three had cerebral
metastases, and the remaining 13 had organ failure (Fig 1). A total of
347 patients were included in the study. RVT was detected in 242
patients (69.7%) who were then randomly assigned to continue (119
patients; groupA1)ordiscontinue (123patients; groupA2) treatment
with LMWH. RVT was absent in 105 patients (30.3%; group B).
Baseline patient characteristics are reported in Table 1. Cancer char-
acteristics, site, and chemotherapy treatments in each group are re-
ported in Tables 1 and 2. Twenty-three percent of patients had a
hematologic cancer, mostly lymphoma (29 [35.8%] of 81; Table 2).
Considering the prevalence of metastatic cancer, cancer types, and
ongoing chemotherapy, there were no statistically significant differ-
ences between groups.
Outcomes
Overall, 18 of the 119 patients in group A1 developed recurrent
VTE compared with 27 of 123 patients in group A2. The 12-month
cumulative recurrent VTE rates were 15.1% and 21.9%, respectively.
The adjustedHR for groupA2 versus A1was 1.58 (95%CI, 0.8 to 3.0;
P .175). Three of the 105 patients in group B developed recurrent
VTE. The 12-month cumulative rate of recurrence was 2.8% (Table
3). The adjusted HR for group A2 versus group B was 9.56 (95% CI,
2.8 to 28.5; P  .001), although adjusted HR for group A1 versus
group B was 6.0 (95%CI, 1.7 to 21.2; P .005).
In total, 30 isolated DVTs of the lower limbs occurred among
groups; in 12 patients, thrombosis occurred in the contralateral leg.
In detail, four DVTs of the contralateral leg occurred in group A1,
seven in group A2, and only one in group B. None of the contralat-
eral DVTs occurred in patients with recurrent DVT and PE.
Bleeding events are reported inTable 3. Threemajor bleedings
occurred in group A1, and two events each occurred in groups A2
and B (P  .880). Considering the 6- and 12-month follow-up
periods separately, at 6 months, four VTE were reported and two
major bleeding episodes occurred in group A1; 18 VTE were re-
ported and three bleeding episodes occurred in group A2. At 12
months after random assignment, 10 VTE and two bleeding epi-
sodes were recorded in group A1, whereas group A2 had nine VTE
and one bleeding episode. After the first 6 months, there were 111
patients still on follow-up in group A1 and 101 in group A2. At 12
Table 1. Baseline Characteristics by Patient Group
Characteristic
Group A1
(n  119)
Group A2
(n  123)
Group B
(n  105)
PNo. % No. % No. %
Age, years .856†
Mean 61.3 62.1 61.4
SD 14.7 13.7 13.8
Male sex 66 55.4 68 55.3 58 55.2 .999
Body mass index, kg/m2 .618†
Mean 24.1 24.2 23.9
SD 2.9 3.0 3.1
Recent cancer surgery‡ 75 63.0 78 63.4 65 61.9 .970
Chemotherapy§ 54 45.3 57 46.3 42 40.0 .055
Radiotherapy§ 24 20.1 27 21.9 22 20.9 .943
Hormone therapy§ 12 10.0 14 11.3 11 10.4 .945
Central venous catheter§ 48 40.3 48 39.0 34 32.3 .426
Metastasis 54 21.8 55 25.2 48 15.2 .988
Index venous thrombosis .982
DVT at one site (popliteal or
common femoral) 53 44.5 55 44.7 48 45.7
DVT at two sites (popliteal
and common femoral) 66 55.5 68 55.3 57 54.3
Left side 91 76.5 95 77.2 80 76.2 .359
NOTE. Group A1, patients with residual vein thrombosis (RVT) who continued
low-molecular-weight heparin (LMWH) for an additional 6 months; group A2,
patients with RVT randomly assigned to stop LMWH; group B, patients
without RVT who stopped LMWH.
Abbreviations: DVT, deep vein thrombosis; SD, standard deviation.
P value refers to 2 test unless otherwise specified.
†Univariable analysis of variance test.
‡In the past 3 months.
§In the past 3 months or ongoing.
Table 2. Cancer Site and Chemotherapy by Treatment Group
Cancer Site
Group A1
(n  119)
Group A2
(n  123)
Group B
(n  105)
No. % No. % No. %
Lung 6 5.0 6 4.9 4 3.8
GI 6 5.0 6 4.9 5 4.8
Colon 16 13.5 16 13.0 15 14.3
Rectum 10 8.4 10 8.1 10 9.5
Breast 14 11.8 14 11.4 14 13.3
Genitourinary 14 11.8 14 11.4 11 10.5
Head and neck 15 12.6 18 14.6 13 12.4
Blood 28 23.5 28 22.8 25 23.8
Hodgkin lymphoma 7 5.9 6 4.9 5 4.7
Non-Hodgkin lymphoma 4 3.3 4 3.2 3 2.9
Chronic lymphatic leukemia 12 10.1 12 9.8 11 10.5
Multiple myeloma 5 4.2 6 4.9 6 5.7
Other 10 8.4 11 8.9 8 7.6
NOTE. Group A1, patients with residual vein thrombosis (RVT) who continued
low-molecular-weight heparin (LMWH) for an additional 6 months; group A2,
patients with RVT randomly assigned to stop LMWH; group B, patients
without RVT who stopped LMWH.
Table 3. Recurrent Thromboembolic and Bleeding Events by Treatment
Group and Cancer Site
Event
Group A1
(n  119)
Group A2
(n  123)
Group B
(n  105)
PNo. % No. % No. %
Overall events 18/119 15.1 27/123 21.9 3/105 2.8 .0015
Isolated DVT 9/18 50 19/27 70.4 2/3 66.7 .379
DVT and PE 7/18 38.9 7/27 25.9 0 .333
PE only 2/18 11.1 1/27 3.7 1/3 33.3 .183
DVT in not previously
affected leg 4/18 22.2 7/27 25.9 1/3 33.3 .906
Major bleeding 3 2.5 2 1.6 2 1.9 .880
Minor bleeding 7 5.9 8 6.5 5 4.8 .851
Death (as a result of
cancer
progression) 12 10.1 19 15.4 11 10.5 .366
NOTE. Group A1, patients with residual vein thrombosis (RVT) who continued
low-molecular-weight heparin (LMWH) for an additional 6 months; group A2,
patients with RVT randomly assigned to stop LMWH; group B, patients
without RVT who stopped LMWH. No. columns indicate No. of overall events
per total patient group.
Abbreviations: DVT, deep vein thrombosis; PE, pulmonary embolism.
Bonferroni-adjusted P values refer to 2 test.
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months, therewere 97 patients in groupA1 and 82 in groupA2 (Fig
3). Among patients in group A1, compliance was high: 15 of the
119 patients interrupted LMWH for less than 5 days during
study treatment.
Overall, 42patients (12.1%)diedduring12monthsof follow-up,
all for progression of cancer: 12 patients (10.1%) died in groupA1, 19
(15.4%) in group A2, and 11 (10.5%) in group B. No statistically
significant difference was found between groups (P .366). Fatal PE
was not reported.
DISCUSSION
LMWH is currently the standard of care for cancer-related DVT,
and guidelines recommend continuation of treatment as long as
the neoplasm is active.6 However, cancer populations differ sub-
stantially in terms of type, stage, histology and, consequently,
treatment choice20; thus, the duration of LMWH treatment for an
individual patient is unclear. The optimal duration of anticoagu-
lant therapy should be based on tailoring treatment according to
the risk of recurrent VTE. An individual-based approach of tailor-
ing anticoagulant duration based on RVT and D-dimer has been
investigated in noncancer populations,10-13 but data are lacking in
the cancer population. We chose to study RVT rather than
D-dimer because the latter is insensitive to factors affecting blood
coagulation (such as infections or cancer) and can be determined
without interrupting anticoagulation.11-13
In our study, all patients underwent RVT assessment after 6
months of LMWH. In those with residual RVTwho stopped LMWH
(group A2), the incidence of subsequent recurrent VTE was 21.7%
comparedwith 2.8% inpatientswithoutRVTwho stopped treatment
(B), an almost eight-fold increased risk. Thus the 6-month RVT is
prognostic for recurrent VTE and defines a group of patients at low
risk of recurrence. This has obvious implications for clinical prac-
tice: in low-risk patients, short-term anticoagulation reduces the
clinical burden for both the patient and health care system and
substantially reduces the overall risk of bleeding. In the group of
patientswithRVTat 6months, the continuation of LMWHdidnot
reduce the incidence of recurrent VTE. Although there was a trend
in favor of LMWH, it was not significant, likely because of the small
sample size.
Bleedingwas low inall groups inour trial, likelybecause the study
population had already been on 6 months of anticoagulant therapy
before random assignment; those patients with a bleeding tendency
had already self-selected andwere excluded.Nodifferences inmortal-
ity ratesweredetectedbetweengroups.The trialwasunderpowered to
detect mortality differences. The mortality rates were considerably
lower thanrates inother trialsofLMWH, likelybecausepatients inour
trial had to live for 6 months to be eligible.21,22
As in the noncancer population,more than 20%of the recurrent
thrombotic events occurred in the contralateral leg, suggesting that
RVT is also a marker of an underlying prothrombotic state, thus
triggering a sustained hypercoagulability.23
This study has several limitations; first, the trial was not blinded
to patients and treating physicians. However, committee members,
who were unaware of results and treatments, assessed recurrent
events, thus reducing the risk of diagnostic suspicion bias. Moreover,
the rates of events in our patients are in the range of those reported in
the literature.4,23 Second, some concerns may arise about the repro-
ducibility of RVT detection. Before the three Duration of Anticoagu-
lation based on Compression Ultrasonography (DACUS) studies
(Residual Vein Thrombosis Establishes theOptimal Duration ofOral
Anticoagulants [DACUS]; Residual Vein Thrombosis and the Opti-
mal Duration of Low Molecular Weight Heparin in Cancer Patients
With Deep Vein Thrombosis [Cancer-DACUS]; and Absence of Re-
sidual Vein Thrombosis Permits to Withdrawn Oral Anticoagulants
[Exten-DACUS]), we tested RVT assessment on a consecutive series
of 64noncompressible venous segments (popliteal andcommon fem-
oral veins), and results from intra- and interobserver variation assess-
mentamongoperatorswere showntobeadequate (, 0.7403; 95%CI,
0.70 to 0.86).11,24 In clinical management of DVT, the accuracy and
reproducibility of C-US should be improved with training courses.
Third,RVTassessmentwasperformedonlyat studyentry.Wecannot,
however, exclude that during follow-up, some patients, originally
without RVT, could have had abnormal results on repeated testing,
providing a detectable warning sign of recurrent hypercoagulability
and an increased risk of thrombosis. RepeatedRVT in patientswith
an original absence of residual thrombusmay be useful in detecting
a late relapse even if the patient is asymptomatic, but this hypoth-
esis should be assessed in future studies. Furthermore, exclusion of
concomitant PE was based on clinical symptoms, and routine
imaging tests at enrollment were not planned, which could have
interfered with the management of asymptomatic PE. Fourth, the
sample size was quite small. Fifth, in patients without RVT, the
incidence of recurrent VTE was lower (3%) than previously re-
ported.However, if we consider all the patients enrolled (bothwith
and without RVT), the rate of recurrent VTE was as high as 14%,
which is similar to that reported.4-7 Another potential limitation is
the 6-month difference in follow-up duration between groups A1
and A2, which may have resulted in an underestimate of the event
rate in the latter group.
Our results indicate that, after 6 months of standard treatment
with LMWH for DVT, the absence of RVT identifies patients with
cancer at a low risk for recurrent thrombotic events. This possibility is
important in driving a management strategy for both prevention of
recurrences and selection of patients who may benefit from a short
period of anticoagulation.
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